SODIUM CHLORIDE

Manufacturer
Liebel-Flarsheim Company LLC | Avantor Performance Materials, Inc.
Effective date
2022-12-20
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
16
Source
full-release
Hydrated at
2026-05-31 20:45:50

Label at a glance#

ProductSODIUM CHLORIDE
Active ingredientSODIUM CHLORIDE
Label structure12 sections

Indications and uses

125 mL Syringe:  Sodium Chloride Injection USP 0.9% is indicated for use in flushing compatible contrast agents through Liebel-Flarsheim intravenous administration sets into indwelling intravascular access devices only when delivered by the following Liebel-Flarsheim power injectors: Angiomat ® , Illumena ® , Illumena ® Néo, CT9000 ® , CT9000 ® ADV, Optistat ® , Optivantage ® and Optistar Elite.

Dosage and administration

The 125 mL syringe are for single patient use only. Determine the volume of the saline flush for each patient individually based, in part, on the imaging procedure, the location of the vascular access device, the length of tubing between the Liebel-Flarsheim contrast agent power injector and the vascular access device and the recommendations made on the package insert for the contrast agent. Typical Sodium Chlorid...

Storage and handling

Sodium Chloride Injection USP 0.9% is a clear, colorless, odorless solution containing 9 mg/mL of sodium chloride. Sodium Chloride Injection USP 0.9% is supplied in 125 mL prefilled syringes containing 125 mL of solution. Each syringe is sealed with rubber closures and the contents are sterile. The 125 mL syringe is supplied with a luer locknut adapter which is cleared for manufacture and distribution as a device ...

Label contents#

Full prescribing information#

1 INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

  • 125 mL Syringe:  Sodium Chloride Injection USP 0.9% is indicated for use in flushing compatible contrast agents through Liebel-Flarsheim intravenous administration sets into indwelling intravascular access devices only when delivered by the following Liebel-Flarsheim power injectors: Angiomat®, Illumena®, Illumena® Néo, CT9000®, CT9000® ADV, Optistat®, Optivantage® and Optistar Elite.

2 DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

  • The 125 mL syringe are for single patient use only.
  • Determine the volume of the saline flush for each patient individually based, in part, on the imaging procedure, the location of the vascular access device, the length of tubing between the Liebel-Flarsheim contrast agent power injector and the vascular access device and the recommendations made on the package insert for the contrast agent. Typical Sodium Chloride Injection USP 0.9% flush volumes following contrast agent administration in adults are 10 to 25 mL per injection at rates not to exceed 10 mL/sec.
  • Use of some Liebel-Flarsheim contrast agent power injectors allows for additional infusion of Sodium Chloride Injection USP 0.9% to maintain the patency of vascular access. Typical infusion rates used for this purpose are in the range of 0.5 to 1 mL per minute.
  • Individualize infusion rates and flush volumes for each patient based on their body weight, fluid status and concomitant medical conditions.
  • Consult the Liebel-Flarsheim contrast agent power injector manual for proper use.

2.1 Drug Handling

SPL UNCLASSIFIED SECTION

  • Inspect the syringe for signs of break in sterility.
  • Do not use if the syringe or its tip cap shows signs of damage, leakage or displacement.
  • Do not use if the solution is hazy, cloudy, discolored or contains particulate matter.
  • Use aseptic technique.
  • Expel residual air in both the syringe and tubing prior to connection with the patient’s vascular access.
  • Instructions for assembly and inspection of the Sodium Chloride Injection USP 0.9% syringes prior to use are printed on this sheet.

2.2 125 mL Syringe Assembly and Inspection

SPL UNCLASSIFIED SECTION

NOTE: Exterior of syringe is not sterile.
Contents of syringe and area under tip cap and piston ribs are sterile and should be treated accordingly.

Inspecting the 125 mL syringeInspecting the 125 mL syringe

Remove syringe from carton and inspect the area around the tip cap and outside of piston for signs of leakage.  Do not use if leakage is observed.  Load syringe into power injector.

Twisting off the 125 mL syringe capTwisting off the 125 mL syringe cap

To remove tip cap from syringe, push in and twist off, then discard. 
The area under the cap is sterile.  Caution should now be used when handling.

Luer locknut detailLuer locknut detail

Removing cap from luer locknutRemoving cap from luer locknut

Next remove cap from luer locknut dust cover by twisting to break tamper evident seal.  Discard cap.

Attaching luer locknut to syringeAttaching luer locknut to syringe

Attach luer locknut to syringe by holding dust cover and screwing to the stop.
Remove and discard dust cover when ready to attach sterile connector tubing.

3 DOSAGE FORMS AND STRENGTHS

DOSAGE FORMS & STRENGTHS SECTION

Sodium Chloride Injection USP (0.9%)

  • a clear, colorless, odorless solution
  • supplied in 125 mL prefilled syringes
  • contents are sterile

4 CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

None

5 WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS SECTION


5.1 Air Embolism

SPL UNCLASSIFIED SECTION

Remove all air from the syringe and associated tubing prior to injection to avoid air embolus with the associated risk of stroke, organ ischemia and/or infarction, and death.

5.2 Infectious Complications

SPL UNCLASSIFIED SECTION

Use of a damaged syringe or failure to maintain aseptic technique may result in infection, sepsis and death [see Dosage and Administration (2)].

5.3 Fluid Overload

SPL UNCLASSIFIED SECTION

Sodium Chloride Injection USP 0.9% may cause fluid overload in patients with congestive heart failure, severe renal insufficiency, and in clinical states with edema, sodium retention, or hypernatremia.

Consider each patient’s age, body weight, fluid status, concomitant medical conditions and planned radiological procedure to determine if use of Sodium Chloride Injection USP 0.9% is appropriate.

5.4 Extravasation

SPL UNCLASSIFIED SECTION

Extravasation of the Sodium Chloride Injection USP 0.9% may cause mechanical compression of neurovascular structures. Extravasation of contrast agent may result in tissue injury by osmolar and direct cytotoxicity (see package inserts of specific contrast agents). Establish intravascular catheter patency prior to the administration of Sodium Chloride Injection USP 0.9%.

6 ADVERSE REACTIONS

ADVERSE REACTIONS SECTION


Reported adverse reactions include:


  • air embolization with stroke, chest pain, and dyspnea
  • arrhythmia
  • hypotension
  • myocardial infarction
  • sepsis
  • febrile response
  • local tenderness
  • infection at the site of injection
  • venous thrombosis or phlebitis extending from injection site
  • extravasation
  • fluid overload
  • hypervolemia

8 USE IN SPECIFIC POPULATIONS

USE IN SPECIFIC POPULATIONS SECTION


8.1 Pregnancy

PREGNANCY SECTION

Risk Summary
Administration of Sodium Chloride Injection USP 0.9% is not known to cause major birth defects, miscarriage or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with Sodium Chloride Injection USP 0.9.%

All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

8.2 Lactation

LACTATION SECTION

Risk Summary
Appropriate administration of Sodium Chloride Injection USP 0.9% is not known to cause harm to a breastfed infant.

8.4 Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness of Sodium Chloride Injection USP 0.9% administered by power injection in pediatric patients have not been established. Administration of Sodium Chloride Injection USP 0.9% to pediatric patients by power injection is not recommended. When performing manual injection of Sodium Chloride Injection USP 0.9% to pediatric patients, take into account the patient’s weight, fluid status, and concomitant medical conditions to determine if use of Sodium Chloride Injection USP 0.9% is appropriate.

The safety of manual injection of Sodium Chloride Injection USP 0.9% in pediatric patients is supported by reported clinical experience with intravenous infusion and flush of sodium chloride injection in pediatric patients.

To minimize the risk of fluid overload, use the smallest dose of Sodium Chloride Injection USP 0.9% necessary for manually flushing contrast agent through the vascular access line.

8.5 Geriatric Use

GERIATRIC USE SECTION

No clinical studies of Sodium Chloride Injection USP 0.9% were conducted. Other reported clinical experience with sodium chloride injection has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

10 OVERDOSAGE

OVERDOSAGE SECTION

Use of Sodium Chloride Injection USP 0.9% may pose a threat of overdose marked by electrolyte disturbance and/or fluid overload, particularly in pediatric patients and patients with compromised renal or cardiac function. In the event of overdosage, discontinue the infusion, reevaluate the patient and institute appropriate corrective action.

11 DESCRIPTION

DESCRIPTION SECTION

Sodium Chloride Injection USP 0.9% is a formulation of sodium chloride in Water for Intravascular Injection. No preservative, antimicrobial agent or buffer is added. Sodium Chloride Injection USP 0.9% is provided as a sterile, nonpyrogenic, clear, colorless, odorless solution.

    Molecular formula = NaCl                   MW = 58.44

Each mL of Sodium Chloride Injection USP 0.9% contains 9 mg of sodium chloride. The pH is 4.5 to 7.0. The osmolarity is 308 mOsm/L (calc.).  

Sodium Chloride Injection USP 0.9% is provided in a 125 mL syringe with a 125 mL fill.  The syringes are for single patient use and are disposable and not meant for reuse.

12 CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Sodium Chloride Injection USP 0.9% has an osmotic pressure similar to plasma.

16 HOW SUPPLIED/STORAGE AND HANDLING

HOW SUPPLIED SECTION

Sodium Chloride Injection USP 0.9% is a clear, colorless, odorless solution containing 9 mg/mL of sodium chloride. Sodium Chloride Injection USP 0.9% is supplied in 125 mL prefilled syringes containing 125 mL of solution. Each syringe is sealed with rubber closures and the contents are sterile. The 125 mL syringe is supplied with a luer locknut adapter which is cleared for manufacture and distribution as a device under 510(K) number 862653. The syringes are contained in shipping cartons with the following configurations:

VolumePackagingNDC
 125 mL
          in plastic syringes
 20 syringes per carton 0019-1188-81
 125 mL
          in plastic RFID-Tagged Syringes*
 20 syringes per carton 0019-1188-27
        *Radio Frequency Identification (RFID) Technology

RFID-Tagged Syringe Description

This information is for Ultraject® syringes containing Sodium Chloride Injection USP 0.9% that has been labeled with a Radio Frequency Identification (RFID) tag.  When used with an RFID-enabled Optivantage Injector, this tag allows for the exchange of product information such as lot number, expiration, concentration, and identification of the syringe as being unused prior to use and used after product administration.  Patient information is not utilized in any form with this RFID technology. Sodium Chloride Injection USP 0.9% product quality is not impacted with the use of this RFID tag. Sodium Chloride Injection USP 0.9% RFID syringes require no special handling and should be stored at the conditions listed for the drug product.

RFID-Tagged Syringe Directions for Use

For the RFID technology to function, the syringe must be used with an Optivantage Injector with RFID technology. Function of the RFID technology is not dependent on syringe orientation as it is placed in the injector. Instructions for use of the injector are provided on the injector interface screens and operator’s manual.

If the RFID tag is damaged or otherwise non-functional, the injector will notify the user.  Should this occur, the Sodium Chloride Injection USP 0.9% syringe with the non-functional RFID tag may still be used but no data will be transferred to the injector.

Regarding interference with medical devices, the RFID tag and injector system meet the IEC 60601-1-2 requirements for emission and immunity standards for medical devices.  Follow all manufacturers’ guidelines and do not operate any part of the Optivantage Injector System and RFID-tagged syringes within 6 inches (15 cm) of a pacemaker and/or defibrillator.

Storage

Store Sodium Chloride Injection USP 0.9% syringes and RFID-tagged syringes at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

PROTECT FROM FREEZING

Manufactured by:
Liebel-Flarsheim Company LLC
Raleigh, NC 27616

Made in USA

GBT 11880919 

Issued: 9/19

Guerbet

PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - 125 mL Syringe

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

For Intravascular Use

Sterile Solution

NDC 0019-1188-81

125 mL

Sodium Chloride Injection USP 0.9%

MEDICATION AND FLUID PATHWAY ARE STERILE.
OUTSIDE OF SYRINGE IS NOT STERILE.

SINGLE DOSE UNIT, DISCARD UNUSED PORTION.
EXPEL AIR BEFORE USE.
PROTECT FROM FREEZING.

Rx only

Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

Each mL contains 9 mg sodium chloride.
Dosage: See package insert.
Discard if syringe seal is broken or leakage is observed.

Manufactured by:Liebel-Flarsheim Company LLC
Raleigh, NC 27616
Made in USA

Guerbet

12070916

Principal Display Panel
Principal Display Panel
Carton
Carton

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
SODIUM CATION Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
95250459-30e4-45c1-b08a-993044f49109Product name220250805
726062af-1135-4707-a1d7-57256991bbf9Product name220250226
a21a21e5-f36d-4c1f-8918-def921b8f7e3Product name320250124
fb7ab793-2c12-4079-b100-a64f73bef25aProduct name420240712
b0cbf770-6cc3-4aa4-9158-755110c2b9f7Product name220230717
dc7c5daa-021f-40dd-b00d-63982cb2067aProduct name120230426
6bd95106-a412-1dad-b9cc-4cb74bfb27ceProduct name220230315
f1e0dc7e-7d61-4625-b6d9-4894927679d7Product name220211025
9badc7be-250a-44ab-aa36-926af3f02679Product name120210527
08ffbcbf-26df-b99c-1dab-64fc4cfae89fProduct name520200925
e4870509-7e28-6f92-f0be-dd3dd889a9cfProduct name520200810
6e9d4a47-c464-b93e-aebc-ad7bffc9c4cdProduct name220190619
444b3e50-f226-46ef-bfca-2e7035d140cdProduct name120190611
816b97af-edc5-4060-aff1-b814bdbcad50Product name120190415
7cda52fc-125f-421c-8fea-bc1974370c49Product name220180703
419aab54-5d5a-4146-9453-026d4a9991beProduct name220170525
26acd337-b838-40ac-bcbc-05c3b81c8712Product name120170323
08ffbcbf-26df-b99c-1dab-64fc4cfae89fProduct name220160823
d5e51f11-ad28-caa4-4b49-4143974782adProduct name120150831
290f523a-f9db-9774-b5a9-e1f908ac1782Product name120150828
0ca1d589-929b-4b33-bc5b-1d84abdafa6aProduct name120150324
fc363c46-397b-4476-ac0f-70e43e8e4592Product name120150324
89dac932-b90a-4410-9ab1-84c53e57de25Product name120150316
19c71a3d-ed9c-166b-a7e5-38c250c35631Product name120140508
5668b646-cd56-c3c7-bdea-3f6b1a8840dbProduct name120140508
597b1cfd-7b31-5048-62be-ca5cd740da2fProduct name120140508
684ea482-2e8b-14af-5664-b98f1e402036Product name120140508
810ab97e-f109-f41c-7c83-6a652a9cbf43Product name120140508
87711080-88eb-65c5-b2dd-bf99e700a372Product name120140508
8dbefedf-0a0d-a224-5a3c-66dc9e11c2ddProduct name120140508
b060cc1a-fe47-856b-0b77-4448b5963de8Product name120140508
c6b65c52-69c7-df49-550a-a50c137f6218Product name120140508
ec2149b3-5c6d-5344-f757-c86411073075Product name120140508
ed912195-5da0-0f2f-6f4b-3ef17710cbe3Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0019-1188-27SODIUM CHLORIDE20 in 1 CARTONINJECTION2016
0019-1188-27SODIUM CHLORIDE1 in 1 BOXINJECTION116
0019-1188-81SODIUM CHLORIDE20 in 1 CARTONINJECTION2016
0019-1188-81SODIUM CHLORIDE1 in 1 BOXINJECTION116

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
0019-1188SODIUM CHLORIDE INJECTION [LIEBEL-FLARSHEIM COMPANY LLC]16Current NDC, Legacy NDC, 4 package rows20221228_e4540d03-06b4-4b4d-b859-75c13e5c20dd.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0019-1188-27ML - Milliliter0019-11886335fb0a-ad2e-43cf-8a6f-fec62d1d959512019-04-11
0019-1188-75ML - Milliliter0019-1188593d5e77-f43a-4242-9252-f717ab33f25012013-02-13
0019-1188-81ML - Milliliter0019-11880702b5e5-f3ba-4a36-8f2a-48a0fef9b89112015-02-02

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
SODIUM CHLORIDEACTIVE INGREDIENT451W47IQ8X7
SODIUM CATIONACTIVE MOIETYLYR4M0NH377
WATERINACTIVE INGREDIENT059QF0KO0R7

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 3 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0019-11880019-1188-81, 0019-1188-27

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 2 matching rows.

Name, UNII, Kind table
NameUNIIKind
SODIUM CHLORIDE451W47IQ8XACTIB
WATER059QF0KO0RIACT

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N021569-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERSODIUM CHLORIDE450MG/50ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-27
N021569-002SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERSODIUM CHLORIDE1.125GM/125ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-27

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 3 · 88 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-10-15 13:18:302026-09N021569-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER450MG/50ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-27c2088c7a36db…
2026-10-15 13:18:302026-09N021569-002SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER1.125GM/125ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-27c2088c7a36db…
2026-09-14 22:38:342026-08N021569-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER450MG/50ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-2784e616aacf4f…
2026-09-14 22:38:342026-08N021569-002SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER1.125GM/125ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-2784e616aacf4f…
2026-08-18 06:07:402026-07N021569-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER450MG/50ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-27caaa826d4ba7…
2026-08-18 06:07:402026-07N021569-002SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER1.125GM/125ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-27caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N021569-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER450MG/50ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-27011fe1cb6892…
2026-02-19 14:30 UTC2026-02N021569-002SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER1.125GM/125ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-27011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N021569-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER450MG/50ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-2731067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N021569-002SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER1.125GM/125ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-2731067a03dcf5…
2025-08-23 18:47 UTC2025-08N021569-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER450MG/50ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-276a471c1ec25d…
2025-08-23 18:47 UTC2025-08N021569-002SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER1.125GM/125ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-276a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N021569-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER450MG/50ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-27fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N021569-002SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER1.125GM/125ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-27fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N021569-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER450MG/50ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-27b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N021569-002SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER1.125GM/125ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-27b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N021569-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER450MG/50ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-2703ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N021569-002SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER1.125GM/125ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-2703ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N021569-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER450MG/50ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-272680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N021569-002SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER1.125GM/125ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-272680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N021569-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER450MG/50ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-275bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N021569-002SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER1.125GM/125ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-275bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N021569-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER450MG/50ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-27d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N021569-002SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER1.125GM/125ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-27d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N021569-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER450MG/50ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-27d06236e962d9…
2024-10-29 15:01 UTC2024-10N021569-002SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER1.125GM/125ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-27d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N021569-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER450MG/50ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-2779d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N021569-002SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER1.125GM/125ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-2779d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N021569-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER450MG/50ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-27301d65b070ca…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N021569-002SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER1.125GM/125ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-27301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N021569-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER450MG/50ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-271e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N021569-002SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER1.125GM/125ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-271e350fbaab3a…
2024-05-31 18:47 UTC2024-05N021569-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER450MG/50ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-278072bd15b7f6…
2024-05-31 18:47 UTC2024-05N021569-002SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER1.125GM/125ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-278072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N021569-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER405MG/50ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-275c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N021569-002SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER1012.5MG/125ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-275c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N021569-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER405MG/50ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-275d02ea3f76ae…
2022-04-08 23:34 UTC2022-04N021569-002SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER1012.5MG/125ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-275d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N021569-001SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER405MG/50ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-274b0b4de00fa7…
2022-04-04 05:41 UTC2022-04N021569-002SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER1012.5MG/125ML (9MG/ML)INJECTABLE / INJECTIONRLD2006-07-274b0b4de00fa7…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
SODIUM CHLORIDESODIUM CHLORIDELiebel-Flarsheim Company LLCe4540d03-06b4-4b4d-b859-75c13e5c20dd2022-12-20Warnings, Adverse reactionsExact identifier
ndc (package): 0019-1188-81
ndc (package): 0019-1188-27
ndc (product): 0019-1188
ndc11 (package): 00019118881
ndc11 (package): 00019118827
spl id: cdff7813-7b00-4f61-a017-18ab8910d49d
spl set id: e4540d03-06b4-4b4d-b859-75c13e5c20dd

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.